Sep 30, 2026 04:47PM
Sep 28, 2026 07:33AM
Sep 18, 2026 06:48AM
Aug 25, 2026 06:59AM
Aug 14, 2026 08:19AM
Jun 11, 2026 06:43AM
Jun 1, 2026 07:26AM Oculis Holding AG (OCS) PT Lowered to $40 at Stifel After Disappointing Ph3 Results
Jun 1, 2026 07:06AM
Jun 1, 2026 06:55AM
May 29, 2026 02:54PM
May 29, 2026 02:45PM
May 20, 2026 04:11PM
May 13, 2026 07:50AM
May 7, 2026 05:59AM Oculis receives FDA agreement on optic neuritis drug trial design
Apr 21, 2026 06:38AM
Mar 5, 2026 06:51AM
Mar 4, 2026 04:46PM
Jan 6, 2026 08:00AM
Dec 19, 2025 07:42AM
Dec 19, 2025 05:16AM
Dec 3, 2025 07:18AM LifeSci Capital Starts Oculis Holding AG (OCS) at Outperform
Oct 7, 2025 06:39AM
Oct 6, 2025 12:09PM
Aug 27, 2025 07:11AM
Aug 22, 2025 06:51AM
Aug 22, 2025 05:33AM
Jun 5, 2025 04:43AM
Apr 15, 2025 03:01PM Stifel Reiterates Buy Rating on Oculis Holding AG (OCS)
Apr 10, 2025 08:04AM
Mar 13, 2025 06:41AM
Mar 12, 2025 09:18AM
Jan 7, 2025 06:52AM
Jan 6, 2025 02:12PM
Oct 21, 2024 05:56AM
Oct 2, 2024 06:13AM Oculis Holding (OCS) Appoints Daniel S. Char as Chief Legal Officer
Sep 5, 2024 05:41AM
Aug 28, 2024 06:43AM
Aug 15, 2024 08:01AM
Jun 11, 2024 06:42AM
Jun 11, 2024 06:36AM
Jun 11, 2024 05:24AM
Jun 10, 2024 04:30AM Oculis Holding (OCS) Reports Positive Topline Results of Phase 2b RELIEF Trial with Licaminlimab

479,029 total articles have been posted to this entity.

Click Here to Sign-Up for StreetInsider.com Premium to View All